Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference

Cancer Biology and Therapy

Volumn 5, Issue 6, 2006, Pages 608-614

  Wang, Liguo ^a   Wu, Guojun ^a   Yu, Lei ^a   Yuan, Jianlin ^a   Fang, Fang ^b   Zhai, Zhenbo ^a   Wang, Fuli ^a   Wang, He ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JILIN MEDICAL COLLEGE   (China)

Author keywords

CD147; Gene therapy; Invasion; Matrix metalloproteinase; Prostate cancer; RNA interference; Small interfering RNA

Indexed keywords

CD147 ANTIGEN; DOUBLE STRANDED DNA; GELATINASE A; GELATINASE B; MESSENGER RNA; SMALL INTERFERING RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INVERTED REPEAT; METASTASIS; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 33745768853     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.6.2661     Document Type: Article

References (59)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Freuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349:906-10.
3. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996; 14:12-21.
4. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28:555-65.
5. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20:3199-205.
6. Oesterling JE, Suman VJ, Zinke H, Bostwick DG. PSA detected (clinical stage T1c or B0) prostate cancer: Pathological significant tumors. Urol Clin North Am 1993; 20:687-93.
7. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated cancer? J Urol 1994; 152:1843-9.
8. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50:6130-8.
9. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55:434-9.
10. Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 1993; 53:3154-8.
11. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997; 272:24-7.
12. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002; 99:520-8.
13. Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R, Gladson CL. Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 2003; 113:1406-10.
14. Polette M, Gilles C, Marchand V, Lorenzato M, Toole B, Tournier JM, Zucker S, Birembaut P. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem 1997; 45:703-9.
15. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70:561-73.
16. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 1999; 47:1575-80.
17. Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC. The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 2001; 276:46870-7.
18. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002; 99:520-28.
19. Bordador LC, Li X, Toole B, Chen B, Regezi J, Zardi L, Hu Y, Ramos DM. Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 2000; 85:347-52.
20. Hou L, Li Y, Jia YH, Wang B, Xin Y, Ling MY, Lü S. Molecular mechanism about lymphogen- ous metastasis of hepatocarcinoma cells in mice. World J Gastroenterol 2001; 7:532-6.
21. Roeb E, Schleinkofer K, Kernebeck T, Potsch S, Jansen B, Behrmann I, Matern S, Grotzinger J. The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem 2002; 277:50326-32.
22. Wang TN, Albo D, Tuszynski GP. Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 2002; 132:220-5.
23. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, Birembaut P. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002; 19:697-702.
24. Menashi S, Serova M, Ma L, Vignot S, Mourah S, Calvo F. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 2003; 63:7575-80.
25. Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000; 60:888-91.
26. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, Foda HD, Tompkins DC, Toole BP. Tumorigenic potential of extracellular matrix metalloproteinase inducer (EMMPRIN). Am J Pathol 2001; 158:1921-8.
27. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003; 1:420-7.
28. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61:2276-81.
29. Lakka SS, Jasti SL, Kyritsis AP, Yung WK, Ali-Osman F, Nicolson GL, Rao JS. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000; 18:253-60.
30. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmuller G. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002; 20:387-92.
31. Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, Koono M, Wakisaka S. Expression of EMMPRIN (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 2000; 88:21-7.
32. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151:665-70.
33. Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: Correlation with invasive growth of breast cancer. World J Surg 2000; 24:334-40.
34. Thorns C, Feller AC, Merz H. EMMPRIN (CD147) is expressed in Hodgkin's lymphoma and anaplastic large cell lymphoma: An immunohistochemical study of 60 cases. Anticancer Res 2002; 22:1983-6.
35. Tang W, Hemler ME. Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J Biol Chem 2004; 279:11112-8.
36. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 2004; 15:4043-50.
37. Toole BP. EMMPRIN (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003; 54:371-89.
38. Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T, Guo H, Hung HC, Toole B, Gallay P, Sherry B, Bukrinsky M. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277:22959-65.
39. Pushkarsky T, Yurchenko V, Vanpouille C, Brichacek B, Vaisman I, Hatakeyama S, Nakayama KI, Sherry B, Bukrinsky MI. Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. J Biol Chem 2005; 280:27866-71.
40. Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, Li JD, Basbaum C. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett 1998; 441:88-92.
41. Taylor PM, Woodfield RJ, Hodgkin MN, Pettitt TR, Martin A, Kerr DJ, Wakelam MJ. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002; 21:5765-72.
42. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65:3193-9.
43. Jiang JL, Yu MK, Chen ZN, Chan HC. cGMP-regulated storeoperated calcium entry in human hepatoma cells. Cell Biol Int 2001; 25:993-5.
44. Pupa SM, Menard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 92:259-67.
45. Sauer CG, Kappeler A, Spath M, Kaden JJ, Michel MS, Mayer D. Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 2004; 444:518-26.
46. Stetler-Stevenson WG, Yu AE. Proteases in invasion: Matrix metalloproteinases. Semin Cancer Biol 2001; 11:143-52.
47. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet 1990; 6:121-5.
48. Lochter A, Bissell MJ. An odyssey from breast to bone: Multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999; 107:128-36.
49. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S, Nakajima M. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79:96-101.
50. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58:1395-9.
51. Knox JD, Bretton L, Lynch T, Bowden GT, Nagle RB. Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 1998; 35:248-54.
52. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998; 152:591-6.
53. Jeffrey Nemeth A, Rafid Yousif, Michael Herzog, Mingxin Che, Jyoti Upadhyay, Bijan Shekarriz, Sunita Bhagat, Chadwick Mullins, Rafael Fridman, Michael Cher L. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. Journal of the National Cancer Institute 2002; 94:17-25.
54. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550-3.
55. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002; 99:1443-8.
56. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002; 20:505-8.
57. Koscioiek BA, Kaiantidis K, Tabler M, Rowley PT. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2003; 2:209-16.
58. Caplen NJ. RNAi as a gene therapy approach. Exp Opin Biol Ther 2003; 3:575-86.
59. Bernd HW, Hatton D, Merz H, Feller AC, Lange K. Matrix-metalloproteinases in Hodgkin lymphoma. Anticancer Res 2003; 23:1555-8.